Insmed Incorporated (INSM)
Largest Insider Buys in Sector
INSM Stock Price History Chart
INSM Stock Performance
About Insmed Incorporated
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a …
Insider Activity of Insmed Incorporated
Over the last 12 months, insiders at Insmed Incorporated have bought $0 and sold $61.62M worth of Insmed Incorporated stock.
On average, over the past 5 years, insiders at Insmed Incorporated have bought $961,331 and sold $21.64M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $385,800 was made by SHAROKY MELVIN MD (director) on 2023‑05‑15.
List of Insider Buy and Sell Transactions, Insmed Incorporated
| 2024-12-19 | Sale | Chair and CEO | 25,580 0.0142% | $69.91 | $1.79M | +0.23% | ||
| 2024-12-12 | Sale | Chair and CEO | 25,580 0.0143% | $72.98 | $1.87M | -0.58% | ||
| 2024-09-16 | Sale | Chief Medical Officer | 13,436 0.008% | $74.92 | $1.01M | -0.63% | ||
| 2024-09-13 | Sale | Chief Medical Officer | 26,969 0.0157% | $74.90 | $2.02M | -2.47% | ||
| 2024-09-13 | Sale | Chief Legal Officer | 27,871 0.0162% | $74.35 | $2.07M | -2.47% | ||
| 2024-09-10 | Sale | Chief People Strategy Officer | 37,575 0.0218% | $71.50 | $2.69M | +1.81% | ||
| 2024-09-06 | Sale | Chief Medical Officer | 149,002 0.0869% | $71.23 | $10.61M | +2.50% | ||
| 2024-08-12 | Sale | Chief People Strategy Officer | 9,469 0.0057% | $72.49 | $686,408 | -1.36% | ||
| 2024-08-12 | Sale | Chief Legal Officer | 88,070 0.0535% | $72.96 | $6.43M | -1.36% | ||
| 2024-06-10 | Sale | Chief Medical Officer | 21,195 0.0132% | $60.00 | $1.27M | +21.72% | ||
| 2024-06-03 | Sale | Chief People Strategy Officer | 55,000 0.0366% | $55.33 | $3.04M | +30.00% | ||
| 2024-05-30 | Sale | Chief Medical Officer | 21,195 0.0138% | $55.00 | $1.17M | +27.79% | ||
| 2024-05-29 | Sale | Chief Financial Officer | 220,564 0.1386% | $50.00 | $11.03M | +35.89% | ||
| 2024-05-28 | Sale | Chief Financial Officer | 20,724 0.0145% | $50.01 | $1.04M | +51.20% | ||
| 2024-05-28 | Sale | Chief Commercial Officer | 7,852 0.0055% | $49.79 | $390,918 | +51.20% | ||
| 2024-05-28 | Sale | Chief People Strategy Officer | 27,500 0.0191% | $49.53 | $1.36M | +51.20% | ||
| 2024-05-28 | Sale | Chief Medical Officer | 103,806 0.0721% | $49.62 | $5.15M | +51.20% | ||
| 2024-05-28 | Sale | Chief Legal Officer | 44,722 0.031% | $49.53 | $2.22M | +51.20% | ||
| 2024-05-17 | Sale | Chief Operating Officer | 5,945 0.004% | $25.09 | $149,160 | +193.01% | ||
| 2024-05-17 | Sale | Chief Medical Officer | 4,642 0.0032% | $25.09 | $116,468 | +193.01% |
Insider Historical Profitability
| Lewis William | Chair and CEO | 233924 0.1308% | $70.97 | 7 | 26 | +45.59% |
| Adsett Roger | Chief Operating Officer | 149275 0.0834% | $70.97 | 1 | 17 | +43.16% |
| ALLAN GEOFFREY | President, CEO and Chairman | 1166464 0.652% | $70.97 | 1 | 0 | +1.39% |
| ENGELSEN STEINAR J | director | 320802 0.1793% | $70.97 | 9 | 0 | +12.65% |
| SHAROKY MELVIN MD | director | 298615 0.1669% | $70.97 | 13 | 7 | +30.85% |
Institutional Investor Ownership
| The Vanguard Group | $393.64M | 8.9 | 14.51M | +2.72% | +$10.41M | 0.01 | |
| BlackRock | $320.13M | 7.24 | 11.8M | +2.67% | +$8.34M | 0.01 | |
| T. Rowe Price | $292.17M | 6.6 | 10.77M | +0.05% | +$151,792.92 | 0.04 | |
| Fidelity Investments | $252.82M | 5.71 | 9.32M | +83.02% | +$114.69M | 0.02 | |
| State Street | $160.21M | 3.62 | 5.91M | -0.42% | -$672,986.78 | 0.01 |